Home Search Abstracts Browse Sessions Program Committee Conference Webcasts Contact Us

Session 92   Poster Abstracts
Emergence of Resistance to Specific Drugs and Drug Combinations
Wednesday, 1:30 - 3:30 pm
Poster Hall
656Pathways to Atazanavir Resistance in Treatment-experienced Patients and Impact of Residue 50 Substitutions
R Colonno*1, N Parkin1,2, C McLaren1, D Seekins3, S Hodder3, S Schnittman1, and T Kelleher1
1Bristol-Myers Squibb Pharm. Res. Labs., Wallingford, CT, USA; 2ViroLogic Inc., South San Francisco, CA, USA; and 3Bristol-Myers Squibb Virology, Plainsboro, NJ, USA
657
Genotypic Resistance Analysis in Women Who Received Intrapartum Nevirapine Associated to a Short Course of Zidovudine to Prevent Perinatal HIV-1 Transmission: The Ditrame Plus ANRS 1201/02 Study, Abidjan, Côte d'Ivoire
M L Chaix*1, C Montcho2, D K Ekouevi3, F Rouet2, L Bequet3, I Viho3, P Fassinou4, C Welfens-Ekra5, V Leroy6, F Dabis6, C Rouzioux1, and The Ditrame Plus Study Group
1CHU Necker, Paris, France; 2CeDreS, Prgm. PACCI, Abidjan, Ivory Coast; 3Projet ANRS Ditrame Plus, Prgm. PACCI, Abidjan, Ivory Coast; 4CHU Yopougon, Abidjan, Ivory Coast; 5CHU Yopougon, Abidjan, Ivory Coast; and 6INSERM U593, Bordeaux, France
658
Mutations at Codon 135 at Baseline Are Associated with the Accumulation of NNRTI-resistance Mutations while on EFV-containing Regimens
C Vavro*, A Florance, D Irlbeck, B Wine, and M St Clair
GlaxoSmithKline, Research Triangle Park, NC, USA
659Evolution of HR1 and HR2 Mutations in HIV-1 gp41 Associated with Long-term Enfuvirtide Therapy
L Xu*1, A Pozniak2, A Wildfire2, D Ratcliffe1, J Workman1, A Joall1, E Smit1, P A Cane1, and D Pillay3
1Hlth. Protection Agency, Birmingham, UK; 2Chelsea and Westminster Hosp., London, UK; and 3Univ. Coll. London, London, UK
660Genetic and Phenotypic Characteristics of Enfuvirtide-resistant HIV-1 Isolates Evolved in vivo after Long-term Treatment
A Monachetti1, A Castagna2, P Bagnarelli1, H Hasson2, A Lazzarin2, M Clementi2, and S Menzo*1
1Univ. of Ancona, Italy and 2San Raffaele Vita-Salute Univ., Milan, Italy
661
Treatment Emergent Mutations for Previously Naïve HIV-infected Adults Failing ZDV+3TC+EFZ and ABC+3TC+EFV
D Irlbeck*, E Rouse, S Castillo, T Scott, W Spreen, H Zhao, J Hernandez, and E R Lanier
GlaxoSmithKline, Research Triangle Park, NC, USA
662Relative Superiority of an Initial Antiretroviral Strategy Is Not Determined only by Frequency of Emergence of HIV Drug Resistance and Cross-resistance
V Johnson1, R Shafer2, L Smeaton3, V DeGruttola3, M Winters2, J Hazelwood1, L Sutton4, B Griffin3, S Snyder5, M Hirsch6, T Merigan2, M Wantman3, G Robbins6, R D'Aquila*4, and The Adult ACTG 384 Protocol Team
1Birmingham VA Med. Ctr and Univ. of Alabama at Birmingham Sch. of Med., USA; 2Stanford Univ. Med. Ctr., CA, USA; 3Statistical and Data Analysis Ctr. (SDAC), Harvard Sch. of Publ. Hlth., Boston, MA, USA; 4Vanderbilt Univ. Sch. of Med., Nashville, TN, USA; 5Social and Sci. Systems, Inc., Silver Spring, MD, USA; and 6Massachusetts Gen. Hosp. and Harvard Med. Sch., Boston, MA